Normal view MARC view ISBD view

Pembrolizumab-Associated Cutaneous and Pulmonary Sarcoidosis in Non-Small Cell Lung Cancer Treatment.

MedStar author(s):

Citation: Clinical Lung Cancer. 23(6):542-546, 2022 09.PMID: 35701321Institution: MedStar Washington Hospital CenterDepartment: DermatologyForm of publication: Journal ArticleMedline article type(s): Case ReportsSubject headings: *Carcinoma, Non-Small-Cell Lung | *Drug-Related Side Effects and Adverse Reactions | *Lung Neoplasms | *Sarcoidosis | *Sarcoidosis, Pulmonary | Antibodies, Monoclonal, Humanized | Carcinoma, Non-Small-Cell Lung/dt [Drug Therapy] | Humans | Lung Neoplasms/di [Diagnosis] | Sarcoidosis, Pulmonary/ci [Chemically Induced] | Sarcoidosis, Pulmonary/di [Diagnosis] | Sarcoidosis/ci [Chemically Induced] | Sarcoidosis/di [Diagnosis]Year: 2022 ISSN:

1525-7304

Name of journal: Clinical lung cancerAbstract: Immune checkpoint inhibitor (ICI) therapy has reshaped the treatment landscape in many cancers including non-small cell lung cancer (NSCLC). ICI-therapy can lead to a diverse array of immune-related adverse effects (irAEs), and prompt recognition and management are key to successful treatment. With wide-spread use of ICI therapy in clinical practice, rare irAEs are being increasingly recognized. This report documents a patient with advanced NSCLC who developed pembrolizumab-associated sarcoidosis with multiorgan involvement. Multidisciplinary management led to timely diagnosis and treatment, leading to improvement in symptoms. This case raises awareness of sarcoidosis as a rare side effect of pembrolizumab. Copyright © 2022. Published by Elsevier Inc.All authors: Cardis M, Dewitt CA, Fleury CM, Holmes M, Kim C, Krochmal R, Sirgi YFiscal year: FY2023 Digital Object Identifier:

https://dx.doi.org/10.1016/j.cllc.2022.05.011

Date added to catalog: 2022-10-20

Holdings ( 1 )
Title notes ( 2 )

Holdings
Item type	Current library	Collection	Call number	Status	Date due	Barcode
Journal Article	MedStar Authors Catalog	Article	35701321	Available		35701321

Immune checkpoint inhibitor (ICI) therapy has reshaped the treatment landscape in many cancers including non-small cell lung cancer (NSCLC). ICI-therapy can lead to a diverse array of immune-related adverse effects (irAEs), and prompt recognition and management are key to successful treatment. With wide-spread use of ICI therapy in clinical practice, rare irAEs are being increasingly recognized. This report documents a patient with advanced NSCLC who developed pembrolizumab-associated sarcoidosis with multiorgan involvement. Multidisciplinary management led to timely diagnosis and treatment, leading to improvement in symptoms. This case raises awareness of sarcoidosis as a rare side effect of pembrolizumab. Copyright © 2022. Published by Elsevier Inc.

English